Skip to content

Long-Term Multi-center Evaluation of E-Poly and Regenerex

Long-Term Multi-center Evaluation of E-Poly and Regenerex Cementless Acetabular Components: Clinical and Radiographic Outcomes

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00545285
Enrollment
1000
Registered
2007-10-17
Start date
2007-11-30
Completion date
2023-05-31
Last updated
2017-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of Hip, Traumatic Arthritis of Hip

Keywords

clinical outcomes, radiographic outcomes, total hip arthroplasty, survivorship

Brief summary

There are two distinct aims of this study: 1. This prospective study is designed to document the long-term (10-year) radiographic and clinical outcomes of a new type of highly cross-linked polyethylene liner which contains vitamin E as an anti-oxidant, (E-Poly), in a group of primary total hip arthroplasty subjects. The clinical outcome of E-Poly will be compared to a group of subjects receiving Arcom XL polyethylene. 2. This study is also designed to document the long-term (10-year) radiographic and clinical outcomes of a new cementless acetabular component having a titanium porous surface (Regenerex). The clinical outcome of this new FDA cleared device will be compared a group of subjects receiving an acetabular component having a plasma sprayed surface.

Interventions

PROCEDURETotal Hip Arthroplasty

Surgical implantation of specific hip replacement components for treatment of osteoarthritis

Sponsors

Zimmer Biomet
CollaboratorINDUSTRY
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Subjects requiring primary total hip replacement * Subjects with diagnosis of osteoarthritis or traumatic arthritis * Subjects who demonstrate the ability to return for follow-up for the next 10 years

Exclusion criteria

* Subjects with limited life span * Subjects with difficulty in comprehending study protocol for any reason. * Subjects with inflammatory disease, previous infection or those requiring revision hip surgery. * Subjects with avascular necrosis * Subjects whose bony structures are so small that a femoral head less than 32mm in diameter must be used. * Subjects whose bony structure deviates substantially from the general norm sufficiently to require non-standard techniques and non-standard implants. Specific examples of these are total dislocation of the hip, severe coxa vera deformity, severe forms of multiple epiphyseal dysplasia * Subjects with complex disease entities which significantly increase the risks of the surgery such as any major platelet abnormality, hematological disorder, positive for HIV or any other major medical complication which substantially reduces longevity. * Female subjects that are pregnant or who may suspect they are pregnant or who plan to become pregnant while participating in this study.

Design outcomes

Primary

MeasureTime frame
Polyethylene wear rates from AP radiographsEvaluated at 1,3,5,7 ,10th year over 10 years
Survivorship: length of time implant remains without revisionEvaluated at 1,3,5,7 ,10th year over 10 years
Complications and Adverse EventsEvaluated at 1,3,5,7 ,10th year over 10 years
Incidence of radiolucencies (acetabular component)Evaluated at 1,3,5,7 ,10th year over 10 years
Patient administered Outcome Survey scoresEvaluated at 1,3,5,7 ,10th year over 10 years

Secondary

MeasureTime frame
Subcategories of the outcome scores regarding pain, patient satisfaction, function,general quality of life.1,3,5,7,10 yr over 10 years
Other outcomes that may be relevant.1,3,5,7,10 yr over 10 years
Retrieval analysis1,3,5,7,10 yr over 10 years
Survivorship in subcategories of infection, aseptic loosening and other1,3,5,7,10 yr over 10 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026